


Map of HCC



All sessions take place in the **Auditorium**, unless otherwise stated

Training day: Tuesday 17 May

1300 Entrance 3 Foyer: Registration

Queen's Suite A II
Pre-registrar Stream

- 1330 Welcome
- 1340 Movement Disorders: Too much or too little: Amit Batla
- 1420 Neurology as a career: Biba Stanton & Anna Nagy
- 1440 Developing your CV for a neurology NTN: Laura Midgley

Queen's Suite B II
Registrar Stream

- 1330 Welcome
- 1340 Neurotoxicity of new immuno-oncology treatments: Jeremy Rees
- 1420 Acute neurological emergencies related to inherited metabolic disease in adults: Elaine Murphy

1500 Queen's Suite Foyer: Coffee Break

1520 Queen's Suite A
Pre-registrar & Registrar Session

- 1520 Controversies and challenges in CNS infections: Benedict Michael
- 1600 Q&A
- 1700 Close
- 1930 ABNT dinner, Vivido restaurant

Wednesday 18 May

0900 Opening and Welcome

0915 Plenary Session 1: Neuropsychiatry

Tics and Tourette's: Eileen Joyce, London

Functional cognitive disorder phenotypes in the differential diagnosis of dementia prodromes: Laura McWhirter, Edinburgh

Positively diagnosing and managing FND: Biba Stanton, London

1045 Coffee, Exhibition & Posters



Zogenix Silent Symposium: Navigating rare and complex epilepsies: Deep dive into Dravet syndrome

1115 **||** Parallel Sessions 1&2

Parallel Session 1: Auditorium
Muscle, nerve and quality

- IVIg-exposure and thromboembolic event risk: findings from the UK Biobank: Aisling Carr
- Real-world experience of gene therapy with Onasemnogene-Abeparvovec (Zolgensma®) for patients with SMA-type1 in UK: Vasantha Gowda
- Long-term assessment of efgartigimod in patients with generalised myasthenia gravis: ADAPT+ study interim results: Saiju Jacob
- Project NeuroSafe: safety practice in neurology services: Christopher Kipps
- Multi-centre audit of myotonic dystrophy care in UK: is it the time for national recommendations?: Mohit Litesh
- An audit of pregnancy and outcomes in the congenital myasthenic syndromes: Tatiana Rooney
- Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results: Pamela Shaw

Parallel Session 2: Hall D
Neurodegeneration

- The clinical, imaging, and pathology characteristics of 'late cases' of sporadic CJD in the UK: John Centola
- Degraded speech comprehension is a 'real-world audiogram' for dementia: Jeremy Johnson
- Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service: Christopher Leahy
- Novel complex motor behaviours in LGI1-autoantibody encephalitis: Sophia Michael
- Using 31-phosphorus magnetic resonance spectroscopy (31P-MRS) to identify Parkinson's disease subgroups with bioenergetic dysfunction: Thomas Payne
- Risk factors and Parkinson's disease presentations in primary care in a diverse UK population: Cristina Simonet
- What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?: Cristina Simonet

1230 Lunch, Exhibition, Posters & Symposia



Queen's Suite A, Biogen: Personalised treatment approaches to MS DMT management: the world in 2022 and beyond

Queen's Suite B, Angelini Pharma: Management of drug resistant epilepsy – what's next?

1400 Gordon Holmes Lecture

Cannabis for Parkinson's disease; curse or cure: Susan Fox, Western General Hospital, Toronto

1445  Parallel Sessions 3 & 4

Parallel Session 3: Auditorium
Acute/Vascular/Trauma

- Delivering acute neurology care via the Same Day Emergency Care (SDEC) model: Michelle Balaratnam
- Atypical clinical presentations are common in TIA and minor stroke patients with DWI-MRI confirmed ischaemia: Jonathan Best
- Cavernomas- a randomised effectiveness (CARE) trial: treatment with versus without neurosurgery for symptomatic brain cavernoma: Kirsty Harkness
- Circulating Interleukin-6 predicts carotid plaque severity, vulnerability, and progression in the Cardiovascular Health Study: Joseph Kamtchum Tatuene
- Cardiovascular autonomic failure correlates with cutaneous autonomic denervation and patient symptoms in alpha-synucleinopathies: Shiwen Koay
- Autonomic dysfunction after moderate-severe traumatic brain injury: symptom spectrum and clinical testing outcomes: Lucia Li
- Active elite rugby participation predicts alterations in cortical thickness: Thomas Parker

Parallel Session 2: Hall D
Covid

- Acute inflammatory CNS diseases following vaccination against SARS-CoV-2: Anna Francis
- Effectiveness of COVID-19 vaccines in multiple sclerosis patients receiving disease-modifying therapies in England: Afagh Garjani
- Prevention of neurological complications during COVID-19: a retrospective analysis of the ISARIC4C national cohort: Alexander Grundmann
- COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database: Ryan Keh
- Epilepsy mortality in Wales during COVID-19: William Owen Pickrell
- T-cell response following COVID booster vaccination in seronegative people with multiple sclerosis (MS): Emma Tallantyre

Wednesday 18 May

1600 Coffee, Exhibition & Posters



Zogenix Silent Symposium:
Navigating rare and complex epilepsies: Clinical cases

1630 Plenary Session 2: The neurology of the special senses: The ear and vestibular system

The neurology of the vestibular system - from inner ear to cortex: Barry Seemungal, London

Auditory cognition: Tim Griffiths, Newcastle

Vestibular migraine or PPPD?: Louisa Murdin, London

1800 Studio One: Poster session with discussants 1

Includes trainee and student guided poster tours - see app for details

1900 Drinks reception & posters

Thursday 19 May

0745 ABN Special Interest Groups (SIGs)

|| Auditorium: SIG 1-Multiple Sclerosis & Neuroinflammation

Chairs: *Tarunya Arun and Klaus Schmierer*

Welcome: Tarunya Arun, ABN Advisory group update: Waqar Rashid, Tonic Update: Carolyn Young, StarMS update: Ben Turner, AttackMS & ChariotMS updates: Klaus Schmierer, Octopus Update: Jeremy Chataway, Neurosarcoidosis update: Tarunya Arun, AOB & Close: Tarunya Arun

|| Hall D: SIG 2 - British Peripheral Nerve Society

Chair: *Aisling Carr*

There will be a panel of doctors (with a peripheral nerve interest). Each will present a very brief illustrative case. The main body of the session will be questions from the floor. We are keen for attendees to bring along their peripheral nerve questions and dilemmas.

|| Queen's Suite A: SIG 3 - Clinical relevance of sustainability

Chair: *Sui Wong*

Part 1 | Setting the scene: neurologists speaking about the impact of climate change on various neurological conditions:

- Movement disorder: Jan Coebergh
- Headache: Anna Cohen
- Stroke: Beth Davis

Part 2 | Encouraging action: Guest speaker, Dr Kris de Meyer on how to encourage behaviour change in the context of supporting sustainability and neurology

Part 3 | Taking action: Case studies of what has worked so far, and the Sustainability Special Interest Group (SUS SIG) plans for promoting community and professional networks, including talks from Anjum Misbahuddin and Ann Cheesman
Close: transitioning SUS SIG leadership & voting in of new chair

|| Queen's Suite B: SIG 4 - Epilepsy

Chair: *Lina Nashef* & panel with Laura Mantoan (KCL), Lina Nashef (KCL), Nick Moran (East Kent Hospitals) & Khalid Hamandi (Cardiff University)

Laura Mantoan: NORSE-UK: Introduction to framework, research & database

Arjune Sen: NORSE case presentation

Nick Moran: Introducing the NORSE-UK protocol

Richard Selway: Neuromodulation in status epilepticus and potential applications to NORSE

Open forum and panel discussion, then conclusions: Laura Mantoan

0900 Plenary Session 3: TBI

Not waking up after TBI: David Menon, Cambridge

Managing challenging behaviours in TBI: Mike Dille, London

Predicting outcome in TBI: Good clinical judgment or self-fulfilling nihilism?
Catherine McMahon, Liverpool

Thursday 19 May

1030 Coffee, Exhibition, Posters & Roche Silent Symposium:



Treatment of individuals with type 2 and 3 Spinal Muscular Atrophy (SMA): Latest findings from the SUNFISH clinical trial

1100 Studio One: Poster session with discussants 2

Includes trainee and student guided poster tours - see app for details

1200 ABN Medallist Lecture, Hadi Manji:

From Eldoret to Harrogate – and a life in-between

Citation: Tom Warner

1245 Lunch, Exhibition, Posters & Symposia



Queen's Suite A, Teva UK: Monoclonals for migraine: are they meeting expectations?

Queen's Suite B, Novartis: Does treating early improve patient outcomes in RRMS and SPMS?

1415 AGM

1500 ABN Equality, Diversity & Inclusion committee: Survey results & discussion

Chair: Richard Davenport

Arani Nitkunan, London

1530 Late Breaking News

1545 Coffee, Exhibition, Posters & Roche Silent Symposium:



Treatment of individuals with type 2 and 3 Spinal Muscular Atrophy (SMA): Latest findings from the SUNFISH clinical trial

1615 Plenary Session 4: Future therapeutics/future diagnostics and therapeutics

On trial: Breaking the impasse in neurodegeneration: Nigel Leigh, Brighton

Neurological complications of checkpoint inhibitors: Aisling Carr, London

1715 Regional Opportunities Forum

Following the success at the Edinburgh ABN 2019 conference, the Research Opportunities Forum is a 45 min session to pitch the professional and personal attractions of working in neurology centre regions. This includes research opportunities for both early and established career academics, leading disease-specific models of care and trials, alongside wider attractions of the area.

This year areas will be represented by Pamela Shaw from Sheffield, Rhys Thomas from Newcastle, Anthony Marson from Liverpool, Helen Ford from Leeds and Monty Silverdale from Manchester. The session is especially aimed at those looking for research opportunities, but also consultant colleagues interested in what's going on elsewhere and whether the grass looks greener.

1800 Close

1830 Gala Dinner drinks reception, Royal Hall

Friday 20 May

0700 Funrun / yoga

0745 ABN Special Interest Groups (SIGs)

III Auditorium: SIG 5 - Autonomic

Chairs: Valeria Iodice, Gordon Ingle & Jalesh Panicker

Part 1 | Small fibre involvement in autonomic disorders. This session will include:

- A general introduction to the subject (clinical and research)
- Discuss the clinical relevance of assessing small fibre function and how this helps defining diagnosis and monitoring progression
- Techniques for assessment
- A selection of cases for discussion.

Part 2 | Possible ABN guidelines for the management of neurogenic urogenital dysfunction for the practicing neurologist

III Hall D: SIG 6 - Movement Disorders

Chair: Mark Edwards

III Queen's Suite A: SIG 7 - Acute Neurology, sharing experiences in the UK

Chair: Holger Allroggen

Arani Nitkunan: Providing an acute neurology service at a district general hospital in Croydon

Martin Sadler: Acute Neurology - the Plymouth experience

Barry Seemungal: Re-organising acute neurology care in North West London - a recent experience

Robert Simister: Lessons from the first six months of a pilot neurology - SDEC service in a central London hospital

Q & A panel discussion

III Queen's Suite B: SIG 8 - Neuro-Ophthalmology

Chairs: Gordon Plant and Sui Wong

Interactive case presentation: A neuro-ophthalmic update on low and high intracranial pressure syndromes (see UKNOS.com for programme)

0900 Case presentation competition & top posters

- A novel neurodegenerative disease with multi-system features: Leah Holm-Mercer
- West is best - a strongman with numb feet: Marc Edwards
- An astra-nomical headache: Trisha Mukherjee
- Changing phenotypes, a spectrum over 10 years: Aye Moe
- Back to basics: Nicholas Keyi Sim
- Cryptic confusion: Frederick Vonberg

1015 Practical Neurology Lecture

Are we (just) our brains? Raymond Tallis

1100 Coffee, Exhibition & Janssen Silent Symposium



Presentation on clinical trial data of ponesimod

Friday 20 May

1130  Parallel Sessions 5 & 6

Parallel Session 5: MS and neuroinflammation

- Extended interval dosing of ocrelizumab reduces risk of developing hypogammaglobulinaemia: Christopher Allen
- Longitudinal clinical study of patients with white matter iron rims lesions in multiple sclerosis: Amjad Altokhis
- Clinical relevance and utility of GAD65 antibodies in neurological disease: an eight year cohort study: Rachel Brown
- Impact of rituximab regime on time to relapse in aquaporin-4 antibody positive neuromyelitis spectrum disorder: Moneeb Nasir
- Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS): Ruth Dobson
- Single-cell profiling of MS CSF B cells highlights roles for TNF α and mTORC1 signalling: Benjamin Jacobs
- The clinical and immunological effects of a distinct HLA in patients with CASPR2-antibodies: James Varley

Parallel Session 6: Hall D
Epilepsy and headache

- Network changes predicting language decline following anterior temporal lobe resection: Lawrence Binding
- Long term outcomes of deep brain stimulation for treatment refractory chronic cluster headache and SUNHA: Sanjay Cheema
- Attenuated heart-brain integration predicts functional non-epileptic seizures: Samia Elkommos
- The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths: Gashirai Mbizvo
- Associations between antiepileptic use and hypogammaglobulinaemia: findings from a population-based case-control study using data linkage: Sarah Perrott
- Idiopathic intracranial hypertension: evaluation of births and fertility through the hospital episode statistic dataset 2002-2020: Mark Thaller
- Future approaches to seizure source localisation using optically pumped magnetoencephalography and electrical impedance tomography: Umesh Vivekananda

1245 Lunch, Exhibition, Posters & Symposia



Queen's Suite A, Argenx: Myasthenia Gravis: optimal treatment for today and what the future may hold

Queen's Suite B, AbbVie: The role of agility & adaptability in the treatment of neurological conditions

1415 Plenary Session 5: Updates for the general neurologist

The use and abuse of genetic testing: Helen Grote, London

Challenges in AIE: Sarosh Irani, Oxford

Hereditary muscle disorders for the general neurologist: James Lilleker, Manchester

1545 CPC

Discussant: Rhys Davies, Liverpool

1630 Prize presentations & close